FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: Medium-High
Study : Colorectal cancer in people with Lynch syndrome can include types of cancer found more typically in people without Lynch syndrome
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: People with Lynch syndrome and people with colorectal cancer who may have Lynch syndrome
When people with Lynch syndrome (LS) develop cancer, their tumors typically have a related set of features or biomarkers known as deficient mismatch repair (dMMR) and high microsatellite instability (MSI-High). However, occasionally people with Lynch syndrome have cancers that are proficient in mismatch repair (pMMR or MMR-P) and have microsatellite stability (MSS or MSI-Low) –more like the colorectal cancers found in people without Lynch syndrome. This study shows that 10 percent of people with Lynch syndrome may have these types of cancers. This can change treatment recommendations. (Posted 9/5/24)
Este artículo está disponible en español.
Read More
Relevance: Medium
Research Timeline: Post Approval
Update : News from the FDA: Updates on breast cancer treatment
Relevance: Medium
Research Timeline: Post Approval
Most relevant for: People with BioZorb markers in breast tissue. People who will have a lumpectomy. People interested in cancer-related podcasts.
The FDA updates the risks of using BioZorb Markers, approves a new imaging drug and shares the Oncology Podcast Series. (Posted 8/16/24)
Este artículo está disponible en español.
Read More
Topic : Acupressure for cancer symptom relief
Most relevant for: People diagnosed with cancer
Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Study : Skin cancer among women with an inherited BRCA mutation
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Most relevant for: People with an inherited BRCA mutation
Women with an inherited BRCA1 and BRCA2 mutation have an increased risk of various cancers. Study results suggest that although the risk of non-melanoma skin cancer in these women is similar to the risk of the general population, the risk of melanoma skin cancer is slightly increased. (Posted 7/25/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Topic : The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced HER2-positive cancer
The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)
Este artículo está disponible en español.
Read More
Topic : Experts call for early palliative care for cancer patients
Most relevant for: Cancer patients
People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Yearly breast MRI screening improves outcomes for women with inherited BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with a BRCA1 or BRCA2 mutation who are considering breast MRI screening
An international research study of yearly breast MRI screening among women with BRCA1 and BRCA2 gene mutations found that BRCA1 carriers who had MRI screenings were less likely to die of breast cancer than those who did not. Additional studies with more BRCA2 mutation carriers are needed to determine if yearly breast MRIs reduce deaths from breast cancer in this group. (Posted 6/24/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Update : Targeted therapy for early-stage HER2-positive breast cancer continues to show benefit
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with early-stage HER2-postive breast cancer
People with early-stage HER2-positive breast cancer benefit from targeted therapy. This update includes new data on survival and the length of time without cancer returning. (Posted 6/20/24)
Este artículo está disponible en español.
Read More
Update : News from the FDA: New ovarian cancer treatment and imaging drug
Most relevant for: People with ovarian cancer.
The FDA recently approved a new treatment for some people with ovarian cancer. The FDA also approved a new imaging drug that can help surgeons find and remove ovarian cancer. (Posted 5/30/24)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Ovary removal reduces risk of death from any cause in people with BRCA mutations
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People who have had a risk reducing bilateral oophorectomy
People who test positive for an inherited BRCA1 or BRCA2 mutation can reduce their risk of ovarian cancer by having both ovaries and fallopian tubes removed. A study published in 2024 found an added benefit of this surgery – a lower risk of death from any cause by age 75. (Posted 5/23/24)
Este artículo está disponible en español.
Read More